CFH and hemolytic-uremic syndrome: Relapses of HUS are mostly observed in patients with mutations of MCP (70%-90% of patients have relapses) [17,18], CFH (50%) [17,18], C3 (50%) [18,83,84] and anti-CFH antibodies (40-60%) [18,37].